Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
pegsunercept
- Development stage
- Phase 2
- Lead developer
- Amgen
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes, PEGylated Peptides → Modified Peptides → Peptides
- Administration
- Subcutaneous, Intravenous
01
Overview
Pegsunercept is a PEGylated recombinant fusion protein that acts as a soluble tumor necrosis factor receptor type I (sTNF-RI). It is designed to bind and neutralize tumor necrosis factor alpha (TNF-α), thereby inhibiting its pro-inflammatory activity. Pegsunercept was developed for the treatment of rheumatoid arthritis and has completed Phase II clinical trials. The drug is structurally similar in mechanism to etanercept but differs in being based on the type I TNF receptor and being PEGylated to increase its half-life. The primary developer of pegsunercept is Amgen[1][2][3].
- Other names
- pegsunerceptsTNF-R1sTNF-R-1sTNF-R 1PEG sTNF-RI
02
Targets
LTA (Lymphotoxin-alpha)TNFA (Tumor necrosis factor alpha (soluble))
Beyond the preview
Go deeper on pegsunercept.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on pegsunercept.